Press release
Metastatic Castration-Resistant Prostate Cancer Pipeline Drugs 2024
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
* August 2024:- Janssen Research & Development, LLC- A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer. The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
* August 2024:- Hansoh BioMedical R&D Company- ARTEMIS-003: A Phase 2, Open-label, Multi-center Study to Evaluate Efficacy, Safety, and Pharmacokinetics, of Intravenous Administration of HS-20093 in Patients With Metastasis Castration Resistant Prostate Cancer and Advanced Solid Tumors Who Have Progressed Following at Least One Prior Therapy
* DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
* The leading Metastatic Castration-Resistant Prostate Cancer Companies working in the market include Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
* Promising Metastatic Castration-Resistant Prostate Cancer Therapies in the various stages of development include JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
Request a sample and discover the recent advances in Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration-Resistant Prostate Cancer Overview
Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named "hormone-refractory prostate cancer" and "androgen-independent prostate cancer". However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
* SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
* Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
* HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Find out more about Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Drugs for Metastatic Castration-Resistant Prostate Cancer Treatment [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment
There are approx. 75+ key Metastatic Castration-Resistant Prostate Cancer companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The Metastatic Castration-Resistant Prostate Cancer companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.
DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report covers around 75+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Learn more about the emerging Metastatic Castration-Resistant Prostate Cancer pipeline therapies @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Intravenous
* Subcutaneous
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Metastatic Castration-Resistant Prostate Cancer Companies
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
Dive deep into rich insights for new drugs for Metastatic Castration-Resistant Prostate Cancer Treatment, visit @ Metastatic Castration-Resistant Prostate Cancer Drugs [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
* Coverage- Global
* Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
* Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
For further information on the Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics, reach out @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Metastatic Castration Resistant Prostate cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Castration Resistant Prostate cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Rucaparib: Clovis Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Surface Oncology: SRF 617
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* REGN 4336: Regeneron Pharamceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HP 518: Hinova Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Castration Resistant Prostate cancer Key Companies
* Metastatic Castration Resistant Prostate cancer Key Products
* Metastatic Castration Resistant Prostate cancer- Unmet Needs
* Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
* Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
* Metastatic Castration Resistant Prostate cancer Analyst Views
* Metastatic Castration Resistant Prostate cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-castrationresistant-prostate-cancer-pipeline-drugs-2024]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Pipeline Drugs 2024 here
News-ID: 3628707 • Views: …
More Releases from ABNewswire
Western Pennsylvania Slip and Fall Attorneys at Luxenberg Garbett Kelly & George …
A fall can happen in a split second, but the impact may lead to lasting consequences -especially when it results in a FOOSH injury. The Western Pennsylvania slip and fall attorneys at Luxenberg Garbett Kelly & George P.C. (https://www.lgkg.com/did-you-suffer-a-foosh-injury/) are raising awareness about these common injuries, which often occur during the winter months when surfaces become especially hazardous. Both Lawrence M. Kelly and Joseph A. George are urging the public…
Pol Gazquez Font: Sales Leader Driving Growth and Developing Talent Across Canad …
Halifax, Nova Scotia - Pol Gazquez Font has established himself as a sales professional dedicated to delivering measurable results, building high-performing teams, and creating sustainable growth systems. Recognized for his leadership and proven track record, Pol Gazquez Font has become a trusted name in direct-to-consumer and retail sales campaigns across Canada.
His career began as a student-athlete in the United States, where he studied business on scholarship. The discipline, resilience, and…
Stabilit America Highlights Applications of Fiberglass Roof Panels with Stabilit …
Roofing materials are very important in the realm of modern construction, as they should be long lasting, economical and attractive. Fiberglass roof panels are a few of the numerous choices among several alternatives that have received a reputation of being versatile, long life, and adaptable in various sectors. They are favored by the architects, contractors, and property developers due to their lightweight construction, resistance to weather factors, and the ease…
From Skin Care to Injectables: Kane Medical Aesthetics Highlights Rise of Male A …
In recent years, Calgary has seen a remarkable shift in the way men approach self-care and appearance. What was once considered taboo is now widely accepted, with many men openly exploring cosmetic treatments to refine their look and support their broader aesthetic goals.
This change is fueled by workplace competitiveness, the influence of social media, and advances in medical aesthetics technology that deliver subtle, natural features without downtime. As part of…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
